One of the big winners in the health-care space on Friday was Illumina (ILMN 1.02%), up 10% for the day after the company outlined its strategic vision. The big news from the report was its new genome sequencer machine, designed to process a staggering 20,000 genomes a year, at a price point of $1,000. This price has long been a target for the industry, and Illumina's reaching it should lead to widespread use of its machine. Releasing its sequencer now also gets it out ahead of competitor Life Technologies' (NASDAQ: LIFE) $1,000 sequencer, and it positions Illumina to dominate what could be a $20 billion market. In this video, Fool health-care analyst David Williamson tells investors just how big the potential for Illumina in this space could be, and what to watch for from here.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.